Exaluren Enters Randomized Phase 2b Alport Study
Eloxx Pharmaceuticals dosed the first two participants in EXACT, a randomized, placebo-controlled, delayed-start Phase 2b study of exaluren in nonsense-mutation Alport syndrome. The global study plans to enroll 24 patients with premature stop mutations…
